Having trouble accessing articles? Reset your cache.

Quenching the flames of inflammatory cell death

With a $50M round, Quench is developing first-in-class gasdermin D inhibitors to treat inflammatory diseases.

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death.

RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and Arix Bioscience plc (LSE:ARIX), which co-founded and seeded Quench Bio Inc., also participated.

The company, founded in 2018, is developing oral small molecule inhibitors of gasdermin D (GSDMD) to treat inflammatory diseases such as rheumatoid arthritis and lupus. The funds will provide Quench three years of runway and allow it to bring at least one candidate to the clinic.

“It’s been known for a decade

Read the full 974 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE